Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FB-606
- Development stage
- Preclinical
- Lead developer
- Fortress Biotech
- Modality
- AAV Vectors → Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Administration
- Intramuscular
01
Overview
FB-606 is a preclinical-stage gene therapy candidate developed by Fortress Biotech (formerly Coronado Biosciences) for the treatment of Duchenne Muscular Dystrophy (DMD). The therapy utilizes an adeno-associated virus (AAV) vector to deliver the gene for follistatin, a naturally occurring protein that acts as a potent antagonist to myostatin (growth differentiation factor 8). Myostatin is a key negative regulator of muscle mass; by overexpressing follistatin, FB-606 aims to inhibit myostatin signaling, thereby promoting muscle hypertrophy and potentially slowing the progressive muscle degeneration and weakness characteristic of DMD.
- Other names
- AAV-follistatinrAAV1-CMV-huFollistatin344rAAV-1-CMV-huFollistatin344rAAV 1-CMV-huFollistatin344
Beyond the preview
Go deeper on FB-606.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FB-606.